Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies

Emmanuel Stip, Simon Zhornitsky, Stéphane Potvin, Valerie Tourjman

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


In clinical psychopharmacology, the optimal method of switching from treatment A to treatment B with regard to efficacy and tolerability is an important area of study. We investigated the effects on efficacy and tolerability of switching patients from conventional antipsychotics to ziprasidone. This was a 6-week open-label, randomized study of 54 patients with persistent schizophrenia or schizoaffective disorder. Patients received ziprasidone 40. mg BID for 2. days, with titration up to 80. mg BID thereafter. The switch from conventional antipsychotics to ziprasidone was achieved using one of three discrete schedules: (1) abrupt discontinuation of conventional antipsychotics on day 1; (2) fast taper-50% of conventional antipsychotic dosage on days 1 through 7, followed by discontinuation and (3) slow taper-100% of conventional antipsychotic dosage on days 1 and 2, followed by 50% on days 3 through 7, then discontinuation. We found some evidence that the slow-taper strategy was associated with greater reductions in BPRS total scores early in the study compared to the other two strategies. However, these differences did not remain significant at endpoint, suggesting that there was no overall difference between the strategies.

Original languageEnglish
Pages (from-to)997-1000
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number6
Publication statusPublished - Aug 2010
Externally publishedYes


  • Antipsychotic withdrawal
  • Atypical antipsychotic
  • Positive symptoms
  • Schizophrenia
  • Switch
  • Ziprasidone

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this